GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer

Yuichiro Sawada, Tadahiko Kikugawa, Hiroyuki Iio, Iori Sakakibara, Shuhei Yoshida, Aoi Ikedo, Yuta Yanagihara, Noritaka Saeki, B. Györffy, Takeshi Kishida, Yoichiro Okubo, Yoshiyasu Nakamura, Yohei Miyagi, Takashi Saika, Yuuki Imai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prognosis of patients with progressive prostate cancers that are hormone refractory and/or have bone metastasis is poor. Multiple therapeutic targets to improve prostate cancer patient survival have been investigated, including orphan GPCRs. In our study, we identified G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5A) as a candidate therapeutic molecule using integrative gene expression analyses of registered data sets for prostate cancer cell lines. Kaplan–Meier analysis of TCGA data sets revealed that patients who have high GPRC5A expression had significantly shorter overall survival. PC3 prostate cancer cells with CRISPR/Cas9-mediated GPRC5A knockout exhibited significantly reduced cell proliferation both in vitro and in vivo. RNA-seq revealed that GPRC5A KO PC3 cells had dysregulated expression of cell cycle-related genes, leading to cell cycle arrest at the G2/M phase. Furthermore, the registered gene expression profile data set showed that the expression level of GPRC5A in original lesions of prostate cancer patients with bone metastasis was higher than that without bone metastasis. In fact, GPRC5A KO PC3 cells failed to establish bone metastasis in xenograft mice models. In addition, our clinical study revealed that GPRC5A expression levels in prostate cancer patient samples were significantly correlated with bone metastasis as well as the patient's Gleason score (GS). Combined assessment with the immunoreactivity of GPRC5A and GS displayed higher specificity for predicting the occurrence of bone metastasis. Together, our findings indicate that GPRC5A can be a possible therapeutic target and prognostic marker molecule for progressive prostate cancer.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

G-Protein-Coupled Receptors
Prostatic Neoplasms
Cell Cycle
Cell Proliferation
Neoplasm Metastasis
Bone and Bones
Neoplasm Grading
Clustered Regularly Interspaced Short Palindromic Repeats
cdc Genes
Orphaned Children
Survival
G2 Phase
Cell Cycle Checkpoints
Transcriptome
Heterografts
Cell Division
Therapeutics
Hormones
RNA
Gene Expression

Keywords

  • bone metastasis
  • GPCR
  • GPRC5A
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. / Sawada, Yuichiro; Kikugawa, Tadahiko; Iio, Hiroyuki; Sakakibara, Iori; Yoshida, Shuhei; Ikedo, Aoi; Yanagihara, Yuta; Saeki, Noritaka; Györffy, B.; Kishida, Takeshi; Okubo, Yoichiro; Nakamura, Yoshiyasu; Miyagi, Yohei; Saika, Takashi; Imai, Yuuki.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Sawada, Y, Kikugawa, T, Iio, H, Sakakibara, I, Yoshida, S, Ikedo, A, Yanagihara, Y, Saeki, N, Györffy, B, Kishida, T, Okubo, Y, Nakamura, Y, Miyagi, Y, Saika, T & Imai, Y 2019, 'GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer', International Journal of Cancer. https://doi.org/10.1002/ijc.32554
Sawada, Yuichiro ; Kikugawa, Tadahiko ; Iio, Hiroyuki ; Sakakibara, Iori ; Yoshida, Shuhei ; Ikedo, Aoi ; Yanagihara, Yuta ; Saeki, Noritaka ; Györffy, B. ; Kishida, Takeshi ; Okubo, Yoichiro ; Nakamura, Yoshiyasu ; Miyagi, Yohei ; Saika, Takashi ; Imai, Yuuki. / GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. In: International Journal of Cancer. 2019.
@article{0dadebd6691349eb881fbadb998e7ab2,
title = "GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer",
abstract = "The prognosis of patients with progressive prostate cancers that are hormone refractory and/or have bone metastasis is poor. Multiple therapeutic targets to improve prostate cancer patient survival have been investigated, including orphan GPCRs. In our study, we identified G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5A) as a candidate therapeutic molecule using integrative gene expression analyses of registered data sets for prostate cancer cell lines. Kaplan–Meier analysis of TCGA data sets revealed that patients who have high GPRC5A expression had significantly shorter overall survival. PC3 prostate cancer cells with CRISPR/Cas9-mediated GPRC5A knockout exhibited significantly reduced cell proliferation both in vitro and in vivo. RNA-seq revealed that GPRC5A KO PC3 cells had dysregulated expression of cell cycle-related genes, leading to cell cycle arrest at the G2/M phase. Furthermore, the registered gene expression profile data set showed that the expression level of GPRC5A in original lesions of prostate cancer patients with bone metastasis was higher than that without bone metastasis. In fact, GPRC5A KO PC3 cells failed to establish bone metastasis in xenograft mice models. In addition, our clinical study revealed that GPRC5A expression levels in prostate cancer patient samples were significantly correlated with bone metastasis as well as the patient's Gleason score (GS). Combined assessment with the immunoreactivity of GPRC5A and GS displayed higher specificity for predicting the occurrence of bone metastasis. Together, our findings indicate that GPRC5A can be a possible therapeutic target and prognostic marker molecule for progressive prostate cancer.",
keywords = "bone metastasis, GPCR, GPRC5A, prostate cancer",
author = "Yuichiro Sawada and Tadahiko Kikugawa and Hiroyuki Iio and Iori Sakakibara and Shuhei Yoshida and Aoi Ikedo and Yuta Yanagihara and Noritaka Saeki and B. Gy{\"o}rffy and Takeshi Kishida and Yoichiro Okubo and Yoshiyasu Nakamura and Yohei Miyagi and Takashi Saika and Yuuki Imai",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32554",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer

AU - Sawada, Yuichiro

AU - Kikugawa, Tadahiko

AU - Iio, Hiroyuki

AU - Sakakibara, Iori

AU - Yoshida, Shuhei

AU - Ikedo, Aoi

AU - Yanagihara, Yuta

AU - Saeki, Noritaka

AU - Györffy, B.

AU - Kishida, Takeshi

AU - Okubo, Yoichiro

AU - Nakamura, Yoshiyasu

AU - Miyagi, Yohei

AU - Saika, Takashi

AU - Imai, Yuuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The prognosis of patients with progressive prostate cancers that are hormone refractory and/or have bone metastasis is poor. Multiple therapeutic targets to improve prostate cancer patient survival have been investigated, including orphan GPCRs. In our study, we identified G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5A) as a candidate therapeutic molecule using integrative gene expression analyses of registered data sets for prostate cancer cell lines. Kaplan–Meier analysis of TCGA data sets revealed that patients who have high GPRC5A expression had significantly shorter overall survival. PC3 prostate cancer cells with CRISPR/Cas9-mediated GPRC5A knockout exhibited significantly reduced cell proliferation both in vitro and in vivo. RNA-seq revealed that GPRC5A KO PC3 cells had dysregulated expression of cell cycle-related genes, leading to cell cycle arrest at the G2/M phase. Furthermore, the registered gene expression profile data set showed that the expression level of GPRC5A in original lesions of prostate cancer patients with bone metastasis was higher than that without bone metastasis. In fact, GPRC5A KO PC3 cells failed to establish bone metastasis in xenograft mice models. In addition, our clinical study revealed that GPRC5A expression levels in prostate cancer patient samples were significantly correlated with bone metastasis as well as the patient's Gleason score (GS). Combined assessment with the immunoreactivity of GPRC5A and GS displayed higher specificity for predicting the occurrence of bone metastasis. Together, our findings indicate that GPRC5A can be a possible therapeutic target and prognostic marker molecule for progressive prostate cancer.

AB - The prognosis of patients with progressive prostate cancers that are hormone refractory and/or have bone metastasis is poor. Multiple therapeutic targets to improve prostate cancer patient survival have been investigated, including orphan GPCRs. In our study, we identified G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5A) as a candidate therapeutic molecule using integrative gene expression analyses of registered data sets for prostate cancer cell lines. Kaplan–Meier analysis of TCGA data sets revealed that patients who have high GPRC5A expression had significantly shorter overall survival. PC3 prostate cancer cells with CRISPR/Cas9-mediated GPRC5A knockout exhibited significantly reduced cell proliferation both in vitro and in vivo. RNA-seq revealed that GPRC5A KO PC3 cells had dysregulated expression of cell cycle-related genes, leading to cell cycle arrest at the G2/M phase. Furthermore, the registered gene expression profile data set showed that the expression level of GPRC5A in original lesions of prostate cancer patients with bone metastasis was higher than that without bone metastasis. In fact, GPRC5A KO PC3 cells failed to establish bone metastasis in xenograft mice models. In addition, our clinical study revealed that GPRC5A expression levels in prostate cancer patient samples were significantly correlated with bone metastasis as well as the patient's Gleason score (GS). Combined assessment with the immunoreactivity of GPRC5A and GS displayed higher specificity for predicting the occurrence of bone metastasis. Together, our findings indicate that GPRC5A can be a possible therapeutic target and prognostic marker molecule for progressive prostate cancer.

KW - bone metastasis

KW - GPCR

KW - GPRC5A

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85069896085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069896085&partnerID=8YFLogxK

U2 - 10.1002/ijc.32554

DO - 10.1002/ijc.32554

M3 - Article

C2 - 31276604

AN - SCOPUS:85069896085

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -